Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-

Nature Medicine

Volumn 2, Issue 10, 1996, Pages 1132-1135

  Hughes, David E ^a,b   Dai, Aihua ^a   Tiffee, John C ^a   Li, He Hiu ^a   Munoy, Gregory R ^a   Boyce, Brendan F ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

17ALPHA ESTRADIOL; ESTROGEN; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; IN VITRO STUDY; MOUSE; NONHUMAN; OSTEOCLAST; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; APOPTOSIS; BONE AND BONES; BONE RESORPTION; CELL COUNT; CELLS, CULTURED; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MICE; MICE, INBRED C57BL; ORGAN SIZE; OSTEOBLASTS; OSTEOCLASTS; OSTEOPOROSIS, POSTMENOPAUSAL; OVARIECTOMY; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA; UTERUS;

ANIMALIA; MURINAE; TRIXIS;

EID: 0029798819     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1096-1132     Document Type: Article

References (27)

1. Melton, L.J. How many women have osteoporosis now? J. Bone. Miner. Res. 10, 175-177 (1995).
2. Lindsay, R. Prevention and treatment of osteoporosis. Lancet 341, 801-805 (1993).
3. Pollard, J.W., Pacey, J., Cheng, S.V.Y. & Jordan, E.G. Estrogens and cell death in murine uterine luminal epithelium. Cell. Tissue Res. 249, 533-540 (1987).
4. Goulding, A., Gold, E. & Feng, W. Tamoxifen in the rat prevents estrogen-deficiency bone loss elicited with the LHRH agonist buserelin. Bone Miner. 18, 143-152 (1992).
5. Oursler, M.J. et al. Modulation of transforming growth factor-β production in normal human osteoblast-like cells by 17β-estradiol and parathyroid hormone. Endocrinology 129, 3313-3320 (1991).
6. Hughes, D.E. et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J. Bone Miner. Res. 10, 1478-1487 (1995).
7. Takahashi, N. et al. Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures. Endocrinology 122, 1473-1482 (1988).
8. Minkin, C. Bone acid phosphatase: Tartrate-resistant acid phosphatase as a marker of osteoclast function. Calcif. Tissue Int. 34, 285-290 (1982).
9. Wesolowski, G. et al. Isolation and characterization of highly enriched, perfusion mouse osteoclastic cells. Exp. Cell Res. 219, 679-686 (1995).
10. Grainger, D.J., Witchell, C.M. & Metcalfe, J.C. Tamoxifen elevates transforming growth factor-β and suppresses diet-induced formation of lipid lesions in mouse aorta. Nature Med. 1, 1067-1073 (1995).
11. Rotello, R.J., Lieberman, R.C., Purchio, A.F. & Gerschenson, L.E. Coordinated regulation of apoptosis and cell proliferation by transforming growth factor β1 in cultured uterine epithelial cells. Proc. Natl. Acad. Sci. USA 88, 3412-3415 (1991).
12. Jilka, R.L. et al. Increased osteoclast development after estrogen loss: Mediation by interleukin-6. Science 257, 88-92 (1992).
13. Liu, C.-C. & Howard, G.A. Bone-cell changes in estrogen-induced bone-mass increase in mice: Dissociation of osteoclasts from bone surfaces. Anat. Rec. 229, 240-250 (1991).
14. Beaudreuil, J. et al. Short-term local injections of transforming growth factor-β 1 decrease ovariectomy-stimulated osteoclastic resorption in vivo in rats. J. Bone Miner. Res. 10, 971-977 (1995).
15. Erlebacher, A. & Derynck, R. Increased expression of TGF-β2 in osteoblasts results in an osteoporosis-like phenotype. J. Cell Biol. 132, 195-210 (1996).
16. Pfeilschifter, J., Seyedin, S.M., & Mundy, G.R. Transforming growth factor beta inhibits bone resorption in fetal rat long bone cultures. J. Clin. Invest. 82, 680-685 (1988).
17. Tashjian, A.H., Jr., et al. α and β human transforming growth factors stimulate prostaglandin production and bone resorption in cultured mouse calvaria. Proc. Natl. Acatl. Sci. USA 82, 4535-4538 (1985).
18. Bonewald, L.F. Can transforming growth factor beta be useful as a protective agent for pluripotent hematopoietic progenitor cells? Exp. Hematol. 20, 1249-1251 (1992).
19. Oursler, M.J., Pederson, L., Fitzpatrick, L., Riggs, B.L. & Spelsberg, T. Human giant cell tumors of bone (osteoclastomas) are estrogen target cells. Proc. Natl. Acad. Sci. USA 91, 5227-5231 (1994).
20. Smeyne, R.J. et al. Continuous c-fos expression precedes programmed cell death in vivo. Nature 363, 166-169 (1993).
21. Zheng, M.H. et al. Evidence that human osteoclast-like cells are not the major estrogen target cells. [Abstr.] Bone 16 (suppl.), 93S (1995).
22. Parfitt, A.M. et al. Relationships between surface, volume and thickness of iliac trabecular bone in aging and in osteoporosis. Implications for the microanatomic and cellular mechanisms of bone loss. J. Clin. Invest. 72, 1396-1409 (1983).
23. Parfitt, A.M., Mundy, G.R., Roodman, G.D., Hughes, D.E. & Boyce, B.F. A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates. J. Bone Miner. Res. 11, 150-159 (1996).
24. Horowitz, M.C. Cytokines and estrogen in bone: Anti-osteoporotic effects. Science 260, 626-627 (1993).
25. Garrett, I.R. & Mundy, G.R. Relationship between interleukin-1 and prostaglandins in resorbing neonatal calvaria. J. Bone Miner. Res. 4, 789-794 (1989).
26. 1 induces osteoclast apoptosis in vitro. [Abstr.] J. Bone Miner. Res. 9 (suppl.), S138 (1994).
27. Turner, C.H., Sato, M. & Bryant, H.U. Raloxifene preserves bone strength and bone mass in ovariectomized rats. Endocrinology 135, 2001-2005 (1994).